Biomarkers for personalised breast cancer treatment 
New Methods Improve Breast Cancer Therapy,
New network topology approaches reveal differential correlation patterns in breast cancer. BMC Systems Biology 2013 Aug 15;7:78. doi: 10.1186/1752-0509-7-78
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial. PLoS One. 2013; 8(12): e79775. doi: 10.1371/journal.pone.0079775
The immunogenicity of breast cancer--molecular subtypes matter. Ann Oncol (2014) 25 (8): 1453-1455. doi: 10.1093/annonc/mdu235
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol (2014) 25 (8): 1544-1550. doi: 10.1093/annonc/mdu112
PIK3CA mutations are associated with lower rates of pathological complete response (pCR) to anti-HER2 therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014 Oct 10;32(29): 3212-20. doi: 10.1200/JCO.2014.55.7876.
Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. Pharmacoeconomics. 2015; 33: 179–190. doi: 10.1007/s40273-014-0227-x
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol (2015) 26 (1): 95-100.doi: 10.1093/annonc/mdu487
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol (2015) 26 (2): 259-271.doi: 10.1093/annonc/mdu450
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. J Clin Oncol. 2015 Mar 20;33(9): 983-91. doi: 10.1200/JCO.2014.58.1967
RESPONSIFY partners' presentations on Breast Cancer at ASCO , 2014
The RESPONSIFY Flyer is available on request
Please contact tp21.